Kairos Pharma (NYSEAMERICAN:KAPA) Stock Set to Reverse Split on Tuesday, September 1st

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA – Free Report) shares are scheduled to reverse split on the morning of Tuesday, September 1st. The 1-7 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, August 31st.

Kairos Pharma Trading Down 20.0%

Shares of KAPA stock traded down $0.06 during trading hours on Monday, reaching $0.23. 1,701,340 shares of the company’s stock were exchanged, compared to its average volume of 1,091,567. Kairos Pharma has a 1 year low of $0.22 and a 1 year high of $2.11. The stock has a market cap of $5.50 million, a PE ratio of -0.83 and a beta of 1.56. The stock’s fifty day moving average price is $0.35 and its two-hundred day moving average price is $0.49.

Get Kairos Pharma alerts:

Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter. On average, equities analysts expect that Kairos Pharma will post -0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Kairos Pharma stock. Two Sigma Investments LP acquired a new stake in shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 45,789 shares of the company’s stock, valued at approximately $54,000. Two Sigma Investments LP owned about 0.22% of Kairos Pharma at the end of the most recent reporting period.

Kairos Pharma Company Profile

(Get Free Report)

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.

See Also

• Five stocks we like better than Kairos Pharma
• Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
• Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
• Snowflake Could Be Headed for New Highs Despite Insider Selling
• MongoDB Is Surging—And the Next Catalyst Is Almost Here

Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.